Adaptive Cancer Treatment Solutions for Unique Operational Environments

Publication ID: 24-11857522_0009_PTD
Published: October 28, 2025
Category:Specialized Variations & Niche Solutions

Legal Citation

pr1or.art Inc., “Adaptive Cancer Treatment Solutions for Unique Operational Environments,” Published Technical Disclosure No. 24-11857522_0009_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857522_0009_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,522.

Summary of the Inventive Concept

This inventive concept adapts tucaresol-based compositions for specific, niche markets and extreme operational environments, enhancing cancer treatment accessibility and efficacy.

Background and Problem Solved

The original patent disclosed tucaresol-based compositions for cancer treatment, but it did not address the unique challenges posed by high-altitude regions, disaster relief scenarios, extreme weather conditions, high-security facilities, or remote areas. This inventive concept solves these problems by integrating tucaresol-based compositions with specialized devices, systems, and methods tailored to these specific environments.

Detailed Description of the Inventive Concept

The inventive concept comprises five specialized variations: (1) a system for treating cancer in high-altitude regions, featuring a composition containing tucaresol or its analogs and a device for monitoring oxygen levels; (2) a method for disaster relief, involving administration of a pharmaceutical composition containing tucaresol or its analogs and provision of a portable shelter; (3) a kit for extreme weather conditions, consisting of a pharmaceutical composition containing tucaresol or its analogs and a water-resistant container; (4) a system for treating cancer in high-security facilities, featuring a composition containing tucaresol or its analogs and a biometric authentication device; and (5) a method for treating cancer in remote areas, utilizing a drone delivery system and remote patient response monitoring.

Novelty and Inventive Step

The new claims introduce novel combinations of tucaresol-based compositions with specialized devices, systems, and methods tailored to unique operational environments, which are not obvious from the original patent. The inventive step lies in the adaptation of the original composition to address the specific challenges and limitations of these environments.

Alternative Embodiments and Variations

Alternative embodiments may include integrating tucaresol-based compositions with other specialized devices, such as wearable oxygen sensors, portable power generators, or satellite communication systems. Variations may involve adapting the composition for use in other extreme environments, such as space exploration or deep-sea operations.

Potential Commercial Applications and Market

This inventive concept has significant commercial potential in the pharmaceutical and biotechnology industries, particularly in the areas of cancer treatment, disaster relief, and remote healthcare. The target market includes healthcare providers, governments, and organizations operating in unique operational environments.

CPC Classifications

SectionClassGroup
A A61 A61K31/192
A A61 A61K31/496
A A61 A61K39/3955
A A61 A61P35/00
C C07 C07K16/2818
C C07 C07K16/2827
A A61 A61K2039/505

Field of Art

Pharmaceutical chemistry, specifically cancer immunotherapy and drug delivery systems, involving complex molecular compositions and treatment methodologies for immune system interventions

Person of Ordinary Skill (PHOSITA) Profile

A person with advanced degrees in pharmaceutical sciences, biochemistry, or medical chemistry, possessing expertise in drug formulation, immunological treatments, and adaptive medical technologies with knowledge of cancer therapeutics and delivery mechanisms

Obviousness Rationale

A skilled practitioner would recognize that the PTD represents predictable extensions of the source patent's core composition by applying standard engineering problem-solving techniques to address contextual treatment challenges. The variations demonstrate routine adaptations of known tucaresol-based immunotherapeutic compositions to specific environmental constraints. These modifications represent standard design choices within the pharmaceutical and medical device development domain.

Obvious Combinations & Variations

Source Patent Element
Pharmaceutical composition containing tucaresol analogs with immune checkpoint inhibitors
PTD Variation
Integrating composition with specialized monitoring devices like oxygen level sensors or biometric authentication systems
Obviousness Reasoning
Combining therapeutic compositions with monitoring technologies represents a predictable solution for personalized medical treatment, utilizing known technological integration techniques
Source Patent Element
Cancer treatment composition targeting immune system responses
PTD Variation
Drone delivery and remote patient response monitoring systems
Obviousness Reasoning
Extending pharmaceutical delivery methods to remote environments is a foreseeable technological adaptation addressing accessibility challenges in medical treatment
Source Patent Element
Immune checkpoint inhibitor compositions
PTD Variation
Specialized kits with water-resistant storage containers for extreme environmental conditions
Obviousness Reasoning
Protecting pharmaceutical compositions through specialized packaging represents a standard engineering approach to maintaining drug stability and efficacy
Source Patent Element
Combination immunotherapy using multiple checkpoint inhibitors
PTD Variation
Disaster relief method integrating pharmaceutical administration with portable shelter provisions
Obviousness Reasoning
Contextualizing medical treatments within comprehensive care frameworks is a predictable approach to addressing complex medical intervention scenarios
Source Patent Element
Cancer treatment compositions targeting immune system modulation
PTD Variation
High-security facility treatment system with biometric authentication
Obviousness Reasoning
Implementing secure patient identification protocols with medical treatments represents a standard technological convergence in personalized medical care
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857522, the present publication demonstrates that the claimed variations represent obvious extensions of existing immunotherapeutic compositions through routine technological adaptations. A person having ordinary skill in the art would recognize these modifications as predictable solutions arising from standard problem-solving approaches in pharmaceutical and medical device development, thereby rendering potential derivative claims obvious and unpatentable.

Original Patent Information

Patent NumberUS 11,857,522
TitleCompositions containing tucaresol or its analogs
Assignee(s)BeyondSpring Pharmaceuticals, Inc.